Main Article Content
Many studies pointed to il-6 as hall marker for severity and prognosis of covid-19 patients and represent the most important cornerstone at the discovery of many drugs for inhibition of it for switch-off of cytokine storm which is the concern of all scientists and patients together and a new disease at future medicine as covid-19 begin at last of December 2019. The sources of il-6 after viral stimulation are from macrophages and monocytes at many inflammatory sites or from stimulation of the HPA axis (endocrine il-6 ACTH stimulated) or respiratory il-6 stimulated by strenuous resistive breathing because contracting of respiratory muscles is considered like exercise and produce cytokines due to glycogen depletion
The Discovery of a non-invasive and easy method to examine il-6 which is the most important marker for severity and cytokine storm represent a new horizon for future viruses and modern medicine and that accelerates the intervention and depression of cytokine storm as early as possible and open the door for the discovery of many drugs work on this exhaled il-6 so our method for examination of il-6 at exhaled of covid and postcovid-19 patients help doctors for rapid categorization of patients and suspicion of severity. So, our study is a novel method for examination of il-6 Herein we intend to investigate the level of IL-6 in a breath of COVID-19 patients for the diagnosis of the early stages of lung inflammation and fibrosis. LTB4 is a potent chemoattractant and stimulator of neutrophils, without any significant effect on airway muscle. And increased in exhaled of children with mild and moderate to severe persistent asthma.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2- Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97(12):1299-1302. DOI: 10.1016/j.rmed.2003.07.008
3- Park CS, Chung SW, Ki SY, et al. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1162-1168. doi:10.1164/ajrccm.162.3.9906007
4- Dowlati A, Levitan N, Remick SC. Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. J Lab Clin Med. 1999;134(4):405-409. doi:10.1016/s0022-2143(99)90156-7
5- Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114-120. doi:10.1136/thorax.55.2.114
6- Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Gramiccioni E, Barnes PJ. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J. 2003;21(4):589-593. doi:10.1183/09031936.03.00022203
7- Csoma Z, Kharitonov SA, Balint B, Bush A, Wilson NM, Barnes PJ. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med. 2002;166(10):1345-1349. doi:10.1164/rccm.200203-233OC.
8- Vassilakopoulos T, Zakynthinos S, Roussos C. Strenuous resistive breathing induces proinflammatory cytokines and stimulates the HPA axis in humans [published correction appears in Am J Physiol 1999 Dec;277(6 Pt 2): preceding 1541]. Am J Physiol. 1999;277(4): R1013-R1019. doi:10.1152/ajpregu.1999.277.4. R1013